Verrica Pharmaceuticals Inc Verrica (NASDAQ: VRCA) Stock Down 56% as FDA Decides Not to Authorize Viral Skin Disease Drug VP-102 Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) stock has plummeted 56% after the company confirmed that it has received a Complete Response Letter (CRL) regarding its New Drug Application (NDA) for VP-102
